Poster

HARBOR: A Phase 2/3 Study of BLU-263 in Patients With Indolent Systemic Mastocytosis and Monoclonal Mast Cell Activation Syndrome

Author

M. Castells

Condition

Systemic Mastocytosis and Monoclonal Mast Cell Activation Syndrome

Drug target

KIT D816V

Drug moa

tyrosine kinase inhibitor

Source url

s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-EHA-2022-BLU-263-Non-Advanced-Systemic-Mastocytosis-HARBOR-Trial-In-Progress-Poster.pdf

4 organizations

1 product

Product

Organization

Organization